ライフサイエンスコーパス: deacetylase

1 zed a third enzyme, PgdB, as a glucosamine N-deacetylase.

2 e of SIR2 is SIRT1, an NAD-dependent histone deacetylase.

3 and show it to encode a sirtuin-type histone deacetylase.

4 , belonging to the class of NAD(+)-dependent deacetylases.

5 (PROTAC), which efficiently degrades histone deacetylases.

6 proteases, nitrilases, caspases, and histone deacetylases.

7 d were associated with inhibition of histone deacetylases.

8 se C; nor do they inhibit class I/II histone deacetylases.

9 Histone deacetylase 1 (HDAC1) and HDAC2 are responsible for redu

10 cells had decreased accumulation of histone deacetylase 1 (HDAC1) and HDAC2 at the Cd86 locus.

11 histone acetyl-transferase P300 and histone deacetylase 1 (HDAC1) to circularized HBV DNA (which res

12 NLK can directly phosphorylate histone deacetylase 1 (HDAC1), as well as T cell factor/lymphoid

13 ulating of P53 protein 2 (ASPP2) and histone deacetylase 1 (HDAC1), were also identified.

14 letion of ARID1A resulted in loss of histone deacetylase 1 binding, increased histone 4 lysine acetyl

15 cluster promoted the recruitment of histone deacetylase 1 to specific target gene promoters and, thu

16 can also be induced by inhibition of histone deacetylases 1 and 2 (HCAC 1/2), which is one of the kno

17 Here we report that histone deacetylase 10 (HDAC10) might function as a putative tum

18 erest, pharmacological inhibition of histone deacetylase 11 (HDAC11) and suppressor of variegation 3-

19 Our finding that high levels of histone deacetylase 11 (HDAC11) in human lung tumor tissues corr

20 expression of a chromatin modifier, histone deacetylase 11 (HDAC11).

21 t bacterial-derived lactate inhibits histone deacetylase 11, causing unchecked HDAC6 activity and inc

22 omplexes containing PRMT5 and either histone deacetylase 2 (HDAC2) or HDAC3, enhanced binding of co-a

23 ng variant in the mouse kidney) with histone deacetylase 2 (HDAC2), as well as the function of the Do

24 d a repressive complex by recruiting histone deacetylase 2 to the SIRT3 promoter, and depletion of SR

25 ion, where it interacts with class I histone deacetylases 2 and 3 (HDAC2 and HDAC3) to regulate chrom

26 derived inositol phosphate regulates histone deacetylase 3 (HDAC3) activity in the intestine.

27 hage differentiation program through histone deacetylase 3 (HDAC3) inhibition.

28 Here, we show that histone deacetylase 3 (HDAC3) is a key epigenetic factor require

29 ic manipulations, we determined that histone deacetylase 3 (HDAC3) negatively regulates Nr4a2 in the

30 ression through interaction with the histone deacetylase 3 (HDAC3)-nuclear receptor corepressor 1 (NC

31 er assay developed, we find that the histone deacetylase 3 (HDAC3)-selective inhibitor, RGFP966, inhi

32 in the mouse small intestine through histone deacetylase 3 (HDAC3).

33 and recruiting corepressors such as histone deacetylase 3 (HDAC3).

34 AR2 diminished its interactions with histone deacetylase 3 and beta-catenin, interfering with Wnt coa

35 Histone deacetylases 3 (HDAC3) modulates the acetylation state o

36 factor IIIC subunit 4 and decreased histone deacetylase 5 expression.

37 Inhibition of histone deacetylase 6 (HDAC6) has emerged as a promising therape

38 Histone deacetylase 6 (HDAC6) is a multidomain cytosolic enzyme

39 Histone deacetylase 6 (HDAC6) is an emerging target for the trea

40 Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeut

41 Furthermore, the dynein adapter histone deacetylase 6 (HDAC6) is indispensable for the microtubu

42 Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of

43 Inhibition of histone deacetylase 6 (HDAC6) suppresses the growth of ARID1A-mu

44 e microtubule-associated deacetylase histone deacetylase 6 (HDAC6) via a signaling pathway involving

45 uncoating process is facilitated by histone deacetylase 6 (ref.(1)).

46 ogramming is dependent on functional HISTONE DEACETYLASE 6 and methyltransferase MET1, and transition

47 F2 inhibition, whereas inhibitors of histone deacetylase 6 block the activation of cellular INF2.

48 DNA methyltransferase inhibitors and histone deacetylase 6 inhibitors (DNMTis and HDAC6is) individual

49 Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promis

50 of CAP-KAc-actin-inhibited INF2 with histone deacetylase 6 releases INF2 inhibition, whereas inhibito

51 t SIK1 phosphorylated and stabilized histone deacetylase 7 (HDAC7) protein during cardiac stress, an

52 nt metastatic state was dependent on histone deacetylase 8 activity.

53 Silencing of histone deacetylase 8 led to the inhibition of EphA2 and protein

54 identified a prominent role of HDAC (histone deacetylase)-9 in atherosclerosis and its clinical compl

55 R-335 is epigenetically regulated by histone deacetylases; a screen for suitable histone deacetylase

56 (2020) find that elevated arylacetamide deacetylase (AADAC) expression in vascular smooth muscle

57 ted expression of an esterase, arylacetamide deacetylase (AADAC), in vascular smooth muscle cells (VS

58 Inhibition of histone deacetylases abates c-MYC binding to the promoters of ly

59 owever, point mutations in the NCoR and SMRT deacetylase-activating domains, which are required for H

60 ut how the multi-subunit complexes influence deacetylase activities and site-selectivities in chromat

61 a SIRT6 variant, R65A, that maintains basal deacetylase activity but cannot be activated and failed

62 mpared with acetylated counterparts, but the deacetylase activity can be stimulated by fatty acids an

63 ic SmSirt2 activity in addition to its known deacetylase activity for the first time.

64 wn and NMR experiments, we show that HDAC1/2 deacetylase activity in one of the most ancient and evol

65 is primarily a cytoplasmic protein, and its deacetylase activity is focused mainly on nonhistone sub

66 By contrast, the deacetylase activity of HDAC3 is selectively engaged at

67 The deacetylase activity of HDACs has been shown previously

68 ave been shown to increase the weak in vitro deacetylase activity of SIRT6 but this effect is modest

69 pable of activating the inefficient in vitro deacetylase activity of SIRT6.

70 tail is responsible for a sharp reduction in deacetylase activity of the CoREST complex for H3K14ac.

71 multidomain cytosolic enzyme having tubulin deacetylase activity that has been unequivocally assigne

72 and in vivo experiments showed that CobB(L) deacetylase activity was negatively affected when YiaC a

73 kably higher desuccinylase activity, but not deacetylase activity, in proliferative cultured muscle a

74 ers were a result of direct effects of Hdac3 deacetylase activity, we used an HDAC3 selective inhibit

75 ed by genetic code expansion, stimulates its deacetylase activity.

76 inhibits atherogenesis, all dependent on its deacetylase activity.

77 ntext are largely independent of its histone deacetylase activity.

78 that LDN can bind to SIRT1 and increase its deacetylase activity.

79 Deletion of a gene encoding a putative deacetylase, Agd3, leads to defects in GAG deacetylation

80 icient two-enzyme system, involving a GalNAc deacetylase and a galactosaminidase, for A conversion.

81 king for the synergy observed when combining deacetylase and bromodomain inhibitors.

82 The NAD+-dependent deacetylase and mono-ADP-ribosyl transferase SIRT6 stabi

83 tylase (NuRD) complex uniquely combines both deacetylase and remodeling enzymatic activities in a sin

84 ed tetramers prepared using different chitin deacetylases and observed significant differences in pri

85 and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many validated

86 target associations involving HDACs (histone deacetylases) and sigma receptors by employing modern ap

87 52 repressed PuHDA9, which encodes a histone deacetylase, and led to an increase in acetylation and p

88 ment of ciliary membrane components, histone deacetylase, and transcription factors.

89 cription factors, Mediator subunits, histone deacetylases, and histone tails.

90 ndicate changes in the activity of amidases, deacetylases, and lytic transglycosylases.

91 ruption of cytoskeletal proteins via histone deacetylases, and the recently discovered DNA damage-ind

92 ) through the activity of enzymes known as N-deacetylases, and this N-deacetylation modulates host-pa

93 SIRT6 deacetylase antagonizes ACAT1 function in a manner that

94 de N-deacetylases; however, which of these N-deacetylases are involved in peptidoglycan N-deacetylati

95 l as with nucleosome remodellers and histone deacetylases-at active enhancers and promoters.

96 A deacetylase can remove the acetyl group, thereby restori

97 Sirtuin 1 (Sirt1) is a NAD(+)-dependent deacetylase capable of countering age-related neurodegen

98 produced by three recombinant fungal chitin deacetylases (CDAs) originating from different species,

99 action of chitin synthases (CHSs) and chitin deacetylases (CDAs).

100 e small-molecule inhibitor targeting histone deacetylase class I, is currently in clinical evaluation

101 heterochromatin by outcompeting the histone deacetylase, Clr3 from sites of heterochromatin formatio

102 teractions link Cdk9, H2Bub1 and the histone deacetylase Clr6-CII, while combined Cdk9 inhibition and

103 t with the known control of the Set3 histone deacetylase complex (HDAC) by H3K4 di-methylation, histo

104 The mitotic deacetylase complex (MiDAC) is a recently identified his

105 a component of the nucleosome remodeling and deacetylase complex (NuRD).

106 Saccharomyces cerevisiae, a prion form of a deacetylase complex assembles over subtelomeric domains

107 ncovers a previously uncharacterized histone deacetylase complex in plant immunity and highlights the

108 C-Cdk8, together with the Ume6-Rpd3 histone deacetylase complex, represses the essential autophagy g

109 3), a subunit of NuRD (Nucleosome Remodeling Deacetylase) complex.

110 in structure through the activity of histone deacetylase complexes (HDACs).

111 Class I histone deacetylase complexes play essential roles in many nucle

112 g with the nucleosome remodeling and histone deacetylase complexes.

113 and histone deacetylases families of lysine deacetylases contributed to FUS deacetylation.

114 In the heart, HDACs (histone deacetylases) control remodeling associated processes li

115 on prodrugs with known inhibitors of histone deacetylase, cyclooxygenase, and pyruvate dehydrogenase

116 oine/5-hydroxyectoine hydrolase and the EutE deacetylase degrades both ectoines.

117 three distinct epi-drugs that target histone deacetylase, DNA methylation and bromodomain proteins.

118 The histone deacetylase domain of HDA15 (HDA15HD) assembles as tetra

119 tween the microtubule-binding domain and the deacetylase domain was critical for recognition and effi

120 control the recruitment of chromatin to the deacetylase enzyme, HDAC1/2.

121 lated FUS, whereas both sirtuins and histone deacetylases families of lysine deacetylases contributed

122 IRT2), a member of the NAD-dependent protein deacetylase family, is involved in type I IFN signaling.

123 1, which play a vital role in regulating the deacetylase function of the enzyme and which are absent

124 t multiple nucleosomes implying a processive deacetylase function.

125 y we investigated how the absence of histone deacetylase HDA-2 in the Trichoderma atroviride strain D

126 c interaction between kin-29 and the histone deacetylase hda-4 coupled with subcellular localization

127 auxin/indole-3-acetic acid (AUX/IAA)-histone deacetylase (HDA) and (2) auxin response factor (ARF)-hi

128 auxin/indole-3-acetic acid (AUX/IAA)-histone deacetylase (HDA) and (2) auxin response factor (ARF)-hi

129 acetylase1 (RPD3/HDA1) type class II histone deacetylase HDA15 in Arabidopsis (Arabidopsis thaliana).

130 re and putative elements of the BRAF-histone deacetylase (HDAC) (BHC) chromatin-remodeling complex (L

131 with VPA-mediated inhibition of the histone deacetylase (HDAC) and glycogen synthase kinase-3 (GSK-3

132 study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mT

133 lex (MiDAC) is a recently identified histone deacetylase (HDAC) complex.

134 Histone deacetylase (HDAC) enzymes play a crucial role either as

135 he critical period of plasticity via histone deacetylase (HDAC) inhibition, caused adult stress to pr

136 and consistently modulated following histone deacetylase (HDAC) inhibition; three (H1F0, IRGM, and WI

137 st report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.

138 report that a small-molecule Class 1 histone deacetylase (HDAC) inhibitor Entinostat (MS-275) enhance

139 ation and neutralized effects of the histone deacetylase (HDAC) inhibitor romidepsin.

140 ued by exogenous betaOHB and class I histone deacetylase (HDAC) inhibitor treatment.

141 ase (DNMT) inhibitor hydralazine and histone deacetylase (HDAC) inhibitor valproic acid (VPA) will re

142 The histone deacetylase (HDAC) inhibitor vorinostat disrupts EBV/HHV

143 we found that trichostatin A, a pan-histone deacetylase (HDAC) inhibitor, blocked all high glucose-i

144 umor cells are more sensitive to the histone deacetylase (HDAC) inhibitor-induced loss of stemness th

145 Histone deacetylase (HDAC) inhibitors (HDACis) have been widely

146 rinostat) and selective (romidepsin) histone deacetylase (HDAC) inhibitors elicited metabolic reprogr

147 Histone deacetylase (HDAC) inhibitors may have therapeutic utili

148 th Ac(5)Neu5Ac combined with various histone deacetylase (HDAC) inhibitors, including vorinostat, enh

149 ety by restoring hippocampal class I histone deacetylase (HDAC) levels and activity, specifically HDA

150 odomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promising the

151 n receptor 41 (GPR41) and inhibiting histone deacetylase (HDAC).

152 tanding the roles of various histone/protein deacetylases (HDAC) are key to promoting Treg-based immu

153 harmacological modulation of class I histone deacetylases (HDAC) has been evaluated as a therapeutic

154 which bound to the promoters of the histone deacetylases HDAC1 and HDAC3 and induced HDAC1 and HDAC3

155 Recently, we identified that histone deacetylases HDAC1 and HDAC7 are necessary to maintain c

156 nal KER domain to associate with the histone deacetylases HDAC1/2 and the histone demethylase LSD1, e

157 Tip60 acetylates eEF1A1, whereas the histone deacetylase HDAC2 deacetylates eEF1A1.

158 lysine-specific demethylase Lsd1 and histone deacetylase Hdac2, resulting in the simultaneous removal

159 MutSbeta (Msh2-Msh3 complex) and the histone deacetylase HDAC3 function in the same pathway to drive

160 , we show that Nr4a2 is regulated by histone deacetylase HDAC3 in the aged mouse hippocampus.

161 Here we show that the histone deacetylase HDAC3 inhibits CD8 T cell cytotoxicity early

162 us studies examining the role of the histone deacetylase Hdac3 within myeloid cells demonstrated that

163 ear protein that associates with the histone deacetylase HDAC3.

164 Here we report that class II histone deacetylases HDAC4 and HDAC5 associate with TBX5 and rep

165 Here, we report that class IIa histone deacetylases (HDAC4 and HDAC5) are required for loading-

166 vely regulated by the microtubule-associated deacetylase HDAC6, which functions as a regeneration inh

167 ly significantly modulated protein levels of deacetylase (HDAC8), but also significantly caused dynam

168 I enhanced the activities of Class I histone deacetylases (HDACs 1/2), thereby decreased histone acet

169 egulators physically associated with histone deacetylases (HDACs) and many known players in ASD etiol

170 The histone deacetylases (HDACs) are a superfamily of chromatin-modi

171 Histone deacetylases (HDACs) are an attractive therapeutic targe

172 Histone deacetylases (HDACs) are important regulators of gene ex

173 Histone deacetylases (HDACs) are key enzymes in epigenetics and

174 ivity in the nanomolar range against histone deacetylases (HDACs) as the key target for SAHA.

175 Histone deacetylases (HDACs) have been shown to alleviate renal

176 -42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple mye

177 Histone deacetylases (HDACs) perform multiple functions in regul

178 Class IIa histone deacetylases (HDACs) repress cardiomyocyte hypertrophy t

179 Mammalian histone deacetylases (HDACs) undergo phosphorylation to regulate

180 3/NuRD complex and the activities of histone deacetylases (HDACs), and Tet2 hydroxylase play a critic

181 f lymphomas, including inhibitors of histone deacetylases (HDACs), DNA methyltransferases (DNMTs), en

182 While in mammals, histone deacetylases (HDACs), histone H3 lysine 9 methyltransfer

183 istone acetyltransferases (HATs) and histone deacetylases (HDACs), is necessary for appropriate gene

184 t in PTSD, by (1) altering class IIa histone deacetylases (HDACs), which integrate effects of stress

185 nd gene expression and is removed by histone deacetylases (HDACs).

186 pressed CPI-17 transcription through histone deacetylases (HDACs).

187 to be mediated through the class IIa histone deacetylases (HDACs).

188 tone acetylation via deactivation of histone deacetylases (HDACs).

189 ting gene expression, is mediated by histone deacetylases (HDACs).

190 ion by inhibiting the microtubule-associated deacetylase histone deacetylase 6 (HDAC6) via a signalin

191 is showed that 12 genes potentially encode N-deacetylases; however, which of these N-deacetylases are

192 ph), which signals the recruitment of lysine deacetylase Hst2 and the removal of lysine 16 acetylatio

193 have elucidated a role for the Sir2 histone deacetylase in establishing the normal distribution of M

194 monstrate a role for a mitochondrial protein deacetylase in hippocampal neurons in behavioral and GAB

195 DX39B and histone modifiers such as the SIN3 deacetylase in humans.

196 etion abrogated its interaction with histone deacetylases in astrocytes.

197 otential role of multiple families of lysine deacetylases in the post-translational regulation of DVL

198 al development, but the functions of histone deacetylases in this context are poorly understood.

199 crucial role of HDAC6, a cytoplasmic histone deacetylase, in driving RMS tumor growth, self-renewal,

200 le of Sirtuin 1 (SIRT1), an NAD(+) dependant deacetylase, in improved insulin sensitivity and glucose

201 res, while SIRT6 inhibition using shRNA or a deacetylase-inactive mutant (SIRT6(H133Y)) shortened hum

202 ac, indicating that RPRD proteins recruit K7 deacetylases, including HDAC1.

203 ctivator and repressor, with a non-canonical deacetylase-independent function that is vital for the i

204 o benefit from immune-checkpoint and histone deacetylase inhibition (NCT02395627).

205 roach, we have discovered that rapid histone deacetylase inhibition disrupts super enhancer function

206 hrough mechanisms possibly involving histone deacetylase inhibition.

207 We now show that the FDA-approved histone deacetylase inhibitor (HDACi) valproic acid (VPA) correc

208 uton's tyrosine kinase inhibitor and histone deacetylase inhibitor abrogated refractory B-1b cell imm

209 ith this finding, treatment with the histone deacetylase inhibitor givinostat caused a significant in

210 armaceutical residues in water, is a histone deacetylase inhibitor in mammals, and is reported to low

211 Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1 latency.

212 udied the effect of the FDA-approved histone deacetylase inhibitor suberanilohydroxamic acid (SAHA).

213 Degradation of Dnmt1 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid wa

214 While butyrate is a known histone deacetylase inhibitor that activates expression of many

215 treatment with trichostatin A, a pan-histone deacetylase inhibitor that renders chromatin decondensat

216 y in the nucleus increased following histone-deacetylase inhibitor treatment.

217 nhibitor nicotinamide but not by the histone deacetylase inhibitor trichostatin A.

218 ed to investigate the effects of the histone deacetylase inhibitor valproate and all-trans retinoic a

219 The histone deacetylase inhibitor valproic acid (VPA) is known for i

220 e ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and replicat

221 performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either th

222 be re-activated with Trichostatin A (histone deacetylase inhibitor) and/or 5-aza-dC (an inhibitor of

223 both calcitriol and trichostatin A (histone deacetylase inhibitor), the level of IL-9 reached to the

224 nsisting of sodium butyrate (a broad histone deacetylase inhibitor), UNC0646 (a histone methyltransfe

225 A histone deacetylase inhibitor, TSA, stimulated Rgs16::GFP expres

226 erequisite during the cell cycle and histone deacetylase inhibitor-mediated therapeutics.

227 the well-established synergy between histone deacetylase inhibitors (HDACi) and alkylating agents, we

228 ide hydroxamic acid (vorinostat) are histone deacetylase inhibitors (HDACi) approved by the US Food a

229 Histone deacetylase inhibitors (HDACi) are largely ineffective i

230 Histone deacetylase inhibitors (HDACi) are the most widely studi

231 Clinical trials investigating histone deacetylase inhibitors (HDACi) to reverse HIV-1 latency

232 has been on a class of drugs called histone deacetylase inhibitors (HDACi), which have the potential

233 lecularly targeted agents, including histone deacetylase inhibitors (HDACi).

234 Histone deacetylase inhibitors (HDACIs) may overcome endocrine r

235 Treatment with deacetylase inhibitors also significantly reduced the in

236 Based on the synergism between histone deacetylase inhibitors and hypomethylating agents that w

237 pharmacological activity.IMPORTANCE Histone deacetylase inhibitors are widely studied HIV latency-re

238 ies cell types that are sensitive to histone deacetylase inhibitors based on their metabolic state, a

239 Histone deacetylase inhibitors have been demonstrated to epigene

240 deacetylases; a screen for suitable histone deacetylase inhibitors identified belinostat as a candid

241 h can be reactivated by a mixture of histone deacetylase inhibitors in combination with TNF.

242 rbations could reduce sensitivity to histone deacetylase inhibitors in SS patients.

243 with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg,

244 r amplified by DNA demethylation and histone deacetylase inhibitors providing an exquisite therapeuti

245 In particular, our results with histone deacetylase inhibitors support the view that chromatin a

246 s low-dose DNA methyltransferase and histone deacetylase inhibitors, 5-azacytidine and entinostat, di

247 Histone deacetylase inhibitors, including valproic acid, selecti

248 of PI3K-alpha/delta inhibitors with histone deacetylase inhibitors.

249 ess of the individual in response to histone deacetylases inhibitors (HDACi).

250 SIRT6 (Sirtuin 6) is a nuclear deacetylase involved in DNA damage response signaling, i

251 Our data show that endogenous SIRT6 deacetylase is an important and unrecognized inhibitor o

252 We have discovered that this mitochondrial deacetylase is specifically upregulated in a context-dep

253 Sirtuin 1 (SIRT1), an NAD(+)-dependent deacetylase, is a key regulator of cellular metabolism.

254 SIRT1, a NAD(+)-dependent deacetylase, is pivotal in regulating hepatic gene expre

255 Eleven metal-dependent lysine deacetylases (KDACs) have been identified in human cells

256 alt-inducible kinase 1 (SIK1) stabilized the deacetylase, leading to increased expression of c-Myc, w

257 P-3-O-((R)-3-hydroxymyristoyl)-N-glucosamine deacetylase (LpxC) is as an attractive target for the di

258 The deacetylase module from the NuRD complex contains three

259 xoO and MXAN_3263/ExoP) and a polysaccharide deacetylase (MXAN_3259/ExoL) are important for formation

260 also correlated with enhanced HDAC4 (histone deacetylase) nuclear export, creating a microdomain for

261 and components of nucleosome remodeling and deacetylase (NuRD) are part of the nuclear PERIOD comple

262 The Nucleosome Remodeling and Deacetylase (NuRD) complex uniquely combines both deacet

263 tuin 6 (SIRT6) is a nuclear NAD(+)-dependent deacetylase of histone H3 that regulates genome stabilit

264 ysis of several mutants, we found that the N-deacetylases PdaV and PgdA act in synergy.

265 Sirtuin 7 (SIRT7), an NAD(+)-dependent deacetylase, plays vital roles in energy sensing, but th

266 Inhibition of histone deacetylases promoted accessible chromatin within gene b

267 Mechanistically, SIRT2, an NAD+-dependent deacetylase, protected neurons from cisplatin cytotoxici

268 We find compounds that inhibit histone deacetylase proteins (HDACs) are effective in normalizin

269 these HDAC complexes show a wide variety of deacetylase rates in a site-selective manner.

270 Germline depletion of histone deacetylases revealed that other acetyl marks cannot com

271 termined that the acetyltransferase NuA4 and deacetylase Rpd3 are primarily responsible for the dynam

272 Here, we report that the Set3C histone deacetylase scaffold Snt1 can act as a prion that drives

273 l data on the response of the protein lysine deacetylase SIRT1 to small-molecule activators.

274 utrient/energy sensor mTOR, NAD(+)-dependent deacetylase SIRT1, hypoxia-inducible factor HIF1alpha, o

275 The mitochondrial deacetylase Sirt3 (Sirtuin 3) is critical in the regulat

276 daptations require the mitochondrial protein deacetylase SIRT3 as they are abolished in SIRT3-deficie

277 DLBCLs are dependent on mitochondrial lysine deacetylase SIRT3 for proliferation, survival, self-rene

278 The protein deacetylase SIRT6 maintains cellular homeostasis through

279 Unique among histone deacetylases, SIRT6 possesses the intrinsic capacity to

280 demonstrated that the NAD-dependent protein deacetylase, SIRT7, and the FOXO4 transcription factor a

281 etylation by preserving the NAD(+)-dependent deacetylase sirtuin (Sirt) 1 in human macrophages.

282 itors of a target biomolecule, NAD-dependent deacetylase Sirtuin 1, were identified by a contest-base

283 pigenetic modulators, NAD+ dependent histone deacetylase Sirtuin 2 (SIRT2), which upon infection tran

284 transcriptional repression of mitochondrial deacetylase sirtuin 3 (SIRT3) by androgen receptor (AR)

285 The mitochondrial deacetylase sirtuin 3 (SIRT3) is thought to be one of th

286 The class III histone deacetylase sirtuin 6 (SIRT6) modulates numerous functio

287 The histone deacetylase sirtuin 6 (SIRT6) regulates numerous biologi

288 ect on the enzymatic activity of the histone deacetylase sirtuin family (SIRT1, SIRT2, SIRT3, SIRT5 a

289 NAD-dependent deacetylase sirtuin-1 (SIRT1) is a class III histone dea

290 fasting intervals, increasing NAD-dependent deacetylase sirtuin-1 signaling important for glucose an

291 a (DLBCL) significantly induce mitochondrial deacetylase sirtuin-3 (SIRT3) activity, disrupted mitoch

292 SIRT1 (Sir2) is an NAD(+)-dependent deacetylase that plays critical roles in a broad range o

293 ase sirtuin-1 (SIRT1) is a class III histone deacetylase that positively regulates cancer-related pat

294 f histone deactelyase 6 (HDAC6), a cytosolic deacetylase that regulates tubulin acetylation, in CF mi

295 Hdac3 is a lysine deacetylase that removes acetyl groups from histones and

296 ng on GlcNAc residues, differing from MurNAc deacetylases that lack the metal-coordinating Asp residu

297 as coupled to a switch from type IIa histone deacetylase to p300 histone acetylase binding that corre

298 etabolite that activates a mammalian histone deacetylase to promote epithelial repair.

299 otein complexes that recruit class I histone deacetylases to the genome to regulate gene expression.

300 ytosolic expression ratio for HDAC4 (histone deacetylase type-4).